[1]项朝君,毛琦,田京都,等.比伐卢定在冠状动脉分叉病变介入治疗中的疗效观察[J].第三军医大学学报,2019,41(22):2223-2228.
 XIANG Chaojun,MAO Qi,TIAN Jingdu,et al.Efficacy and safety of bivalirudin in percutaneous coronary intervention for coronary bifurcation lesions[J].J Third Mil Med Univ,2019,41(22):2223-2228.
点击复制

比伐卢定在冠状动脉分叉病变介入治疗中的疗效观察(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第22期
页码:
2223-2228
栏目:
临床医学
出版日期:
2019-11-30

文章信息/Info

Title:
Efficacy and safety of bivalirudin in percutaneous coronary intervention for coronary bifurcation lesions
作者:
项朝君毛琦田京都郑薇王玉清周渝赵晓辉
军军医大学(第三军医大学)第二附属医院全军心血管病研究所
Author(s):
XIANG Chaojun MAO Qi TIAN Jingdu ZHENG Wei WANG Yuqing ZHOU Yu ZHAO Xiaohui

Institute of Cardiovascular Diseases, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China

关键词:
伐卢定冠状动脉疾病经皮冠状动脉介入治疗肝素
Keywords:
 
分类号:
R541.4;R814.47;R973.2
文献标志码:
A
摘要:

目的 观察比伐卢定应用于冠状动脉分叉病变介入治疗中的有效性和安全性。方法本研究为回顾性队列研究,连续纳入2016年1~12月于本所经冠脉造影明确的329例冠脉分叉病变介入治疗患者。按照抗凝方式不同分为肝素组(178例)和比伐卢定组(151例)。统计两组患者的临床资料特征(性别、年龄、危险因素等)与冠脉病变情况,并随访两组患者PCI术后24 h、7 d、1年的主要不良心血管事件(major adverse cardiovascular events, MACE)及出血发生事件,其中MACE包括:死亡、心肌梗死、靶血管再次血管重建、脑卒中,而出血事件参照BARC出血分级标准进行评估。结果两组患者在人口学资料、既往病史、ACS比例、重要实验室指标和药物治疗方面基线数据差异无统计学意义。在分叉病变特征方面,两组患者的分叉病变位置、分叉病变类型、真分叉比例、主支及分支血管的长度和直径差异均无统计学意义。在PCI术后24 h内及1周内,两组均无MACE发生;肝素组有3例患者出现出血事件,无主要出血事件发生;比伐卢定组有5例患者出现出血事件,主要出血事件1例;两组间差异无统计学意义(P=0.477,P=0.459)。随访12个月后,肝素组有20例患者出现MACE,比伐卢定组有15例患者出现MACE,多因素分析显示比伐卢定对分叉病变冠脉介入治疗术后的MACE较肝素组无明显差异(HR=0.839,95%CI:0.420~1.676,P=0.619)。随访12个月后,肝素组有49例患者出现出血事件,主要出血事件6例;比伐卢定组有27例患者出现出血事件,主要出血事件3例;多因素分析显示比伐卢定较肝素显著减少分叉病变介入术后患者出血事件的风险(HR=0.557,95%CI:0.355~0.937,P=0.026);而在主要出血事件风险方面,两者间无明显差异(HR=0.535,95%CI:0.130~2.206,P=0.387)。结论 对冠状动脉分叉病变介入治疗患者随访12个月,比伐卢定较普通肝素显著降低出血风险,而并不增加MACE发生率。

Abstract:

Objective To investigate the efficacy and safety of bivalirudin in percutaneous coronary intervention (PCI) for coronary bifurcation lesions. MethodsThis retrospective cohort study was conducted among 329 consecutive patients with coronary artery bifurcation lesions confirmed by coronary angiography and underwent PCI in our institute between January, 2016 and December, 2016. All the patients received anticoagulation treatment with bivalirudin (151 cases) or heparin (178 cases). The demographic and clinical data of the patients (including gender, age, and risk factors) and the conditions of the coronary artery lesions were compared between the 2 groups. In 24 h, 7 d and 12 months after the procedure, the incidences of main adverse cardiovascular events (MACE, including death, myocardial infarction, revascularization of the target vessel, and stroke) and bleeding were recorded after PCI. The bleeding endpoint was assessed in line with the BARC criteria for grading bleeding. ResultsNo significant differences were found between the 2 groups in the baseline data (including the demographic data, medical history, proportion of acute coronary syndrome, important laboratory indicators, and drug treatment), nor in the characteristics of bifurcation lesions (including the lesion position, lesion type, true bifurcation ratio, length and diameter of the main branches and the branch vessels). In 24 h and 1 week after PCI, no MACE occurred in both groups. Bleeding and observed in 3 cases of the heparin group, but no major bleeding event was seen. In the bivalirudin group, there were 5 cases experiencing bleeding and 1 having major bleeding event. But no significant differonce was seen between the 2 groups (P=0.447, P=0.459). Within 12 months after PCI, MACE occurred in 20 patients in the heparin group and in 15 patients in the bivalirudin group. Multivariate analysis showed that bivalirudin did not significantly affect the incidence of MACE after PCI compared with heparin (HR=0.839, 95%CI: 0.420-1.676, P=0.619). During the 12-month follow-up, 49 patients in the heparin group had bleeding events (including major bleeding events in 6 patients), as compared with 27 patients in the bivalirudin group (including 3 major bleeding events). Multivariate analysis further showed that compared with heparin, bivalirudin significantly reduced the risk of bleeding events in patients with bifurcation lesions after PCI (HR=0.557, 95%CI: 0.355-0.937, P=0.026), but did not significantly affect the risk of major bleeding events (HR=0.535, 95%CI: 0.130-2.206, P=0.387). ConclusionIn patients undergoing PCI for coronary bifurcation lesions, anticoagulation therapy with bivalirudin significantly reduces the risk of bleeding as compared with unfractionated heparin without increasing the incidences of MACE at 12 months after PCI.

参考文献/References:

[1]LASSEN J F,  BURZOTTA F,  BANNING A P, et al. Percutaneous coronary intervention for the left main stem and other bifurcation lesions:  12th consensus document from the European Bifurcation Club[J]. Euro Intervention,  2018,  13(13):  1540-1553. DOI: 10.4244/EIJ-D-17-00622.
[2]LASSEN J F,  HOLM N R,  BANNING A, et al. Percutaneous coronary intervention for coronary bifurcation disease:  11th consensus document from the European Bifurcation Club[J]. EuroIntervention,  2016,  12(1):  38-46. DOI: 10.4244/EIJV12I1A7.
[3]BANNING A P,  LASSEN J F,  BURZOTTA F, et al. Percutaneous coronary intervention for obstructive bifurcation lesions:  the 14th consensus document from the European Bifurcation Club[J]. EuroIntervention,  2019,  15(1):  90-98. DOI: 10.4244/EIJ-D-19-00144. 
[4]QADERDAN K,  VOS G A,  MCANDREW T, et al. Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin:  Pooled analysis from the EUROMAX and HORIZONS-AMI trials[J]. Am Heart J,  2017,  194:  73-82. DOI: 10.1016/j.ahj.2017.08.009.
[5]SANBORN T A,  TOMEY M I,  MEHRAN R, et al. Femoral vascular closure device use,  bivalirudin anticoagulation,  and bleeding after primary angioplasty for STEMI:  results from the HORIZONS-AMI trial[J]. Catheter Cardiovasc Interv,  2015,  85(3):  371-379. DOI: 10.1002/ccd.25663. 
[6]GUERCHICOFF A,  STONE G W,  MEHRAN R, et al. Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction:  results of the HORIZONS-AMI trial[J]. Catheter Cardiovasc Interv,  2015,  85(3):  335-342. DOI: 10.1002/ccd.25620.
[7]STONE G W,  MEHRAN R,  GOLDSTEIN P, et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention:  pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials[J]. J Am Coll Cardiol,  2015,  65(1):  27-38. DOI: 10.1016/j.jacc.2014.10.029.
[8]PATEL H,  GARRIS R,  BHUTANI S, et al. Bivalirudin versus heparin during percutaneous coronary intervention in patients with acute myocardial infarction[J]. Cardiol Res,  2019,  10(5):  278-284. DOI: 10.14740/cr921.
[9]BHOGAL S,  MUKHERJEE D,  BAGAI J, et al. Bivalirudin versus heparin during intervention in acute coronary syndrome:  A systematic review of randomized trials[J]. Cardiovasc Hematol Disord Drug Targets,  2019. DOI: 10.2174/1871529X19666190626124057. [Epub ahead of print]
[10]COHEN D J,  BAKHAI A,  SHI C X, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses:  results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial[J]. Circulation,  2004,  110(5):  508-514. DOI: 10.1161/01.CIR.0000136821.99814.43.
[11]OLMEDO W,  VILLABLANCA P A,  SANINA C, et al. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions:  A systematic review and meta-analysis[J]. Vascular,  2019,  27(1):  78-89. DOI: 10.1177/1708538118807522.
[12]NDREPEPA G,  NEUMANN F J,  DELIARGYRIS E N, et al. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment:  pooled analysis from the ACUITY and ISAR-REACT 4 trials[J]. Circ Cardiovasc Interv,  2012,  5(5):  705-712. DOI: 10.1161/CIRCINTERVENTIONS.112.972869.
[13]NIKOLSKY E,  MEHRAN R,  DANGAS G D, et al. Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction:  analysis from the HORIZONS-AMI trial[J]. Circ Cardiovasc Interv,  2015,  8(4):  e002283. DOI: 10.1161/CIRCINTERVENTIONS.114.002283.
[14]MADHAVAN M V,  GNREUX P,  KIRTANE A J, et al. Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial[J]. Eur Heart J Acute Cardiovasc Care,  2017,  6(7):  650-658. DOI: 10.1177/2048872615592246.
[15]BRENER S J,  MEHRAN R,  LANSKY A J, et al. Pretreatment with aspirin in acute coronary syndromes:  Lessons from the ACUITY and HORIZONS-AMI trials[J]. Eur Heart J Acute Cardiovasc Care,  2016,  5(5):  449-454. DOI: 10.1177/2048872615624848.
[16]VENETSANOS D,  LAWESSON S S,  JAMES S, et al. Bivalirudin versus heparin with primary percutaneous coronary intervention[J]. Am Heart J,  2018,  201:  9-16. DOI: 10.1016/j.ahj.2018.03.014.
[17]SOUZA C F,  DOI H,  MINTZ G S, et al. Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up:  an analysis from the HORIZONS-AMI trial[J]. Coron Artery Dis,  2015,  26(6):  469-475. DOI: 10.1097/MCA.0000000000000251.
[18]WARREN J,  MEHRAN R,  BABER U, et al. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting:  insights from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) and acute catheterization and urgent intervention triage strategy (ACUITY) trials[J]. Am Heart J,  2016,  171(1):  40-47. DOI: 10.1016/j.ahj.2015.07.001.
[19]KIRTANE A J,  SANDHU P,  MEHRAN R,  et al. Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a harmonizing outcomes with revascularization and stents in acute myocardial infarction [HORIZONS-AMI] Substudy)[J]. Am J Cardiol,  2014,  113(1):  36-43.DOI: 10.1016/j.amjcard.2013.08.034.
[20]IBANEZ B,  JAMES S,  AGEWALL S,  et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Rev Esp Cardiol (Engl Ed),  2017,  70(12):  1082.DOI: 10.1016/j.rec.2017.11.010.
 

相似文献/References:

[1]陈剑玲,商黔惠,赵鸿彦,等.原发性高血压患者血尿酸水平与冠状动脉病变程度的相关性分析[J].第三军医大学学报,2012,34(17):1790.
 Chen Jianling,Shang Qianhui,Zhao Hongyan,et al.Correlation between serum uric acid level and severity of coronary artery lesions in patients with essential hypertension[J].J Third Mil Med Univ,2012,34(22):1790.
[2]李飞飞,李莉,刘秋慧,等.经皮冠状动脉介入治疗后普伐他汀对血清基质金属蛋白酶水平的影响[J].第三军医大学学报,2006,28(20):2096.
[3]黄雄,曹雪滨,江明宏,等.单支开放前降支闭塞并休克的介入治疗1例及循证证据[J].第三军医大学学报,2011,33(14):1501.
[4]秦将均,涂蓉,孙清荣.64层螺旋CT冠状动脉成像与冠状动脉造影对照分析[J].第三军医大学学报,2008,30(19):1858.
 QIN Jiang-jun,TU Rong,SUN Qing-rong.Image quality evaluation of 64-slice spiral CT angiography in diagnosis of coronary artery disease[J].J Third Mil Med Univ,2008,30(22):1858.
[5]任洪艳,唐萍,赵庆华.冠心病自我管理量表的开发和评价[J].第三军医大学学报,2009,31(11):1087.
 REN Hong-yan,TANG Ping,ZHAO Qing-hua.Development and evaluation of coronary artery disease self-management scale[J].J Third Mil Med Univ,2009,31(22):1087.
[6]董红梅,黄岚,宋耀明,等.冠心病患者冠脉循环ox-LDL水平与内皮依赖舒张功能关系的研究[J].第三军医大学学报,2006,28(18):1888.
[7]郭应先,刘怀林,袁义强,等.冠状动脉内支架植入对P波离散度的影响[J].第三军医大学学报,2004,26(19):0.[doi:10.16016/j.1000-5404.2004.19.018 ]
[8]程志远,王敏中.66例发作性胸痛患者冠状动脉造影结果分析[J].第三军医大学学报,1996,18(05):0.[doi:10.16016/j.1000-5404.1996.05.041 ]
[9]钟杭美,罗召林,祝善俊,等.动态心电图对冠心病老年患者无症状性与有症状心肌缺血的检测分析[J].第三军医大学学报,1994,16(05):0.[doi:10.16016/j.1000-5404.1994.05.027 ]
[10]何作云,孟惠南,杨国芳,等.冠心病体表心室晚电位的临床意义及影响因素的探讨[J].第三军医大学学报,1990,12(03):0.[doi:10.16016/j.1000-5404.1990.03.010 ]
 He ZuOyun,et al..[J].J Third Mil Med Univ,1990,12(22):0.[doi:10.16016/j.1000-5404.1990.03.010 ]

更新日期/Last Update: 2019-11-21